Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)
Highlights • Bempegaldesleukin is a pegylated interleukin-2 cytokine. • This phase 2 study was conducted in patients previously untreated advanced or metastatic urothelial carcinoma and low PD-L1 expression. • The…